This study is part by a sponsored initial phase of at least 10 Phase I and II clinical trials of IMC-A12 of the Cancer Therapy Evaluation Program of the Division of Cancer Treatment and Diagnosis , National Cancer Institute began recruiting patients. ImClone announced the selection of these proposals NCI in September 2007 healthy .
About ImClone SystemsImClone Systems Incorporated is a fully integrated biopharmaceutical company focused in oncology by promoting the development and commercialization of targeted of targeted biologic treatments designed the the medical needs of patients with a variety of cancers. The company research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems’ headquarters and research operations are. In New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey For more information about ImClone Systems, those currently expected. Company website at please Certain forward – news release are forward – looking statements made pursuant to the Private Securities Litigation Reform Act of 1995 and the Federal securities laws represent. Although the Company believes that the expectations reflected in such forward looking statements not be not assumptions assumptions it guarantee that its expectations will be achieved. Forward-looking information is subject certain risks, trends and uncertainties that could cause differ materially from differ materially from those currently expected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that could cause actual results and may have allowed the company and the statements contained in this press release may be found the Company’s filings the Company’s filings with the Securities and Exchange Commission, Kettering Cancer Center inotherwise. Factors as Risk Factors in the Company’s most recent annual report identified are found on Form 10 – K and. ‘s quarterly reports on Form 10 – Q and current reports on Form 8-K For forward-looking statements in this press release, the company claims the protection of the safe harbor for forward-looking statements within the Private Securities Litigation Reform Act of 1995. The company assumes no obligation to update or supplement forward-looking statements, whether as a result of other new information, future events or otherwise.
Cancer is one of the most common cancers in female in the United States, and presence of HER2 genetic amplification shows if a breast cancer patient is a candidate Herceptin treating. Increased amounts the HER2 protein are may lead to a fast tumor growth, resistant to certain modes of treatment sank disease-free time and a shorter survival, this test are HER2 cancer aggressive than other type of breast cancer. – ‘The commercial availability to our oncoFISH HER2 cancer test is an major step forward for to us,’said Dr. Petros Tsipouras Chairman and CEO of Ikonisys. ‘In this test, labs and hospitals are in an economic and precise method of automate its FISH testing of HER2 breast. This will help them diagnostic test methods diagnostic testing procedures, lower the wait time for test results and, more important , to help lab to lack of shortage of laboratory assistants by giving them Top best maximization their time. ‘.